A novel phosphodiesterase 4/5 dual-target inhibitor ameliorates neuroinflammation via the NF-κB and JNK pathway [0.03%]
一种新型磷酸二酯酶4/5双靶点抑制剂通过NF-κB和JNK途径改善神经炎症
Liyun Zhao,Wenjie Jiang,Yingying Cao et al.
Liyun Zhao et al.
Targeting neuroinflammation is a promising strategy for developing treatments for neurodegenerative diseases. Cyclic nucleotides like cAMP and cGMP, crucial second messengers in the central nervous system. Phosphodiesterases (PDEs) are the ...
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors [0.03%]
一项关于磷酸二酯酶5型抑制剂相关黑色素瘤风险的最新荟萃分析
Michele Kreuz,Francisco Cezar A Moraes,Artur O M Lôbo et al.
Michele Kreuz et al.
Phosphodiesterase type 5 (PDE5) inhibitors are the first-line treatment for erectile dysfunction, with modest adverse effects. Since 2011, concerns have arisen about increased melanoma risk in PDE5 inhibitor users. PDE5 inhibitors affect th...
Impact of Second-Generation PDE 5 Inhibitor, Avanafil, on Retinal Function: Studies From Ex Vivo ERG [0.03%]
第二代磷酸二酯酶5抑制剂阿伐那非对视网膜功能影响的体外研究
Sama Saeid,Frans Vinberg,Ari Koskelainen
Sama Saeid
Purpose: This study investigates whether avanafil, a second-generation phosphodiesterase 5 (PDE5) inhibitor, exhibits reduced off-target effects on retinal function compared to first-generation inhibitors, by quantifying ...
Anna I Malykhina,Svetlana S Efimova,Olga S Ostroumova
Anna I Malykhina
Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation. They have been tested for a broad varie...
Treatment With Phosphodiesterase 5 Inhibitors and Long-Term Outcomes in Patients Undergoing Coronary Angiography and Cardiac Catheterization [0.03%]
磷酸二酯酶5抑制剂治疗与冠状动脉造影和心导管检查患者的长期预后关系的研究
Sumon Roy,Annette Min,Edward O McFalls et al.
Sumon Roy et al.
Background: The effects of phosphodiesterase 5 (PDE5) inhibitors on the incidence of long-term outcomes in patients with cardiovascular disease are not well understood. ...
Phosphodiesterase 5 Inhibitor Improves Insulin Sensitivity by Regulating Adipose Tissue Macrophage Polarization in Diet-Induced Obese Mice [0.03%]
磷酸二酯酶5抑制剂通过调节饮食诱导的肥胖小鼠脂肪组织巨噬细胞极化来改善胰岛素敏感性
Dan-Gyeong Song,Seongwon Pak,Dae-Chul Shin et al.
Dan-Gyeong Song et al.
Background: Obesity is a rapidly increasing global health issue, which is associated with glucose and insulin resistance. Phosphodiesterase type 5 (PDE5) inhibitors (PDE5i) are known for their ability to enhance blood flo...
Prognosis and Treatment With Phosphodiesterase 5 Inhibitors in Combined Post- and Precapillary Pulmonary Hypertension: A Propensity Score-Matched Analysis From the Hellenic Pulmonary Hypertension Registry [0.03%]
结合肺动脉高压的预后和磷酸二酯酶5抑制剂治疗：来自希腊肺动脉高压登记处的倾向性评分匹配分析
Georgios E Papadopoulos,Alexandra Arvanitaki,Sophia-Anastasia Mouratoglou et al.
Georgios E Papadopoulos et al.
Combined post- and precapillary pulmonary hypertension (CpcPH) comprises the most severe form of postcapillary PH. A severe precapillary component (pulmonary vascular resistance [PVR] > 5 WU) is critical for therapeutic decisions. Current t...
Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Patients With Mild or Moderate Hepatic Impairment Versus Participants With Normal Hepatic Function: A Phase I Study [0.03%]
TPN171（一种PDE5抑制剂）在轻度或中度肝功能不全患者中的药代动力学和安全性与正常肝功能受试者相比：一项I期研究
Jing Zhou,Hong Zhang,Yanhua Ding et al.
Jing Zhou et al.
TPN171 is a phosphodiesterase-5 inhibitor. It is currently being developed in China to treat pulmonary arterial hypertension and erectile dysfunction (ED). This study aimed to compare the pharmacokinetics and safety of TPN171 across partici...
Impact of Serum Circulating Factors and PDE5 Inhibitor Therapy on Cardiomyocyte Metabolism in Single Ventricle Heart Disease [0.03%]
单心室疾病中血清循环因素和PDE5抑制剂治疗对心肌细胞代谢的影响
Anastacia M Garcia,Ashley E Pietra,Mary E Turner et al.
Anastacia M Garcia et al.
Background: While operative and perioperative care continues to improve for single ventricle congenital heart disease (SV), long-term morbidities and mortality remain high. Importantly, phosphodiesterase-5 inhibitor thera...
Methylated Arginine Metabolites as Biomarkers for Clinical Status and Response to Type 5 Phosphodiesterase Inhibition in Patients With Fontan Circulation [0.03%]
甲基化精氨酸代谢物作为Fontan循环患者临床状态和5型磷酸二酯酶抑制反应的生物标志物
Ari Cedars,Cedric Manlhiot,Bhargava Kumar Chinni et al.
Ari Cedars et al.
Background: There is significant interest in NO pathway modulators, specifically type 5 phosphodiesterase inhibitors (PDE5is), to treat patients with a Fontan circulation. Trials, however, have had mixed results. The rela...
耗时 0.16736 秒，为您在
48223910
条记录里面共找到 1144 篇文章 [XML]